Emergent BioSolutions (EBS) Gross Profit (2016 - 2025)
Historic Gross Profit for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $145.2 million.
- Emergent BioSolutions' Gross Profit fell 1518.69% to $145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $834.9 million, marking a year-over-year increase of 202.86%. This contributed to the annual value of $767.6 million for FY2024, which is 321.37% up from last year.
- Latest data reveals that Emergent BioSolutions reported Gross Profit of $145.2 million as of Q3 2025, which was down 1518.69% from $74.0 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' Gross Profit registered a high of $534.3 million during Q4 2022, and its lowest value of $11.4 million during Q1 2023.
- Its 5-year average for Gross Profit is $216.4 million, with a median of $163.5 million in 2024.
- In the last 5 years, Emergent BioSolutions' Gross Profit tumbled by 9492.2% in 2023 and then skyrocketed by 126666.67% in 2024.
- Emergent BioSolutions' Gross Profit (Quarter) stood at $292.4 million in 2021, then soared by 82.73% to $534.3 million in 2022, then dropped by 8.05% to $491.3 million in 2023, then fell by 1.89% to $482.0 million in 2024, then plummeted by 69.88% to $145.2 million in 2025.
- Its Gross Profit was $145.2 million in Q3 2025, compared to $74.0 million in Q2 2025 and $133.7 million in Q1 2025.